Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven,
typically present with a low grade at an early stage, and are of endometrioid histology …

Hormonal therapy and chemotherapy play a major role in the management of advanced or
recurrent endometrial cancer. Progesterone therapy obtains overall response rates ranging …

Endometrial carcinoma is the most common cancer of the female reproductive tract.
GPER/GPR30 is a 7‐transmembrane spanning G protein‐coupled receptor that has been …

The molecular underpinnings of high-grade endometrial carcinoma (HGEC) metastatic
growth and survival are poorly understood. Here, we show that ascites-derived and primary …

Recently, the compilation of massive amounts of genetic and genomic information on a wide
variety of human cancer types, collectively known as The Cancer Genome Atlas (TCGA), has …

Background Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal
growth-promoting pathway in endometrial cancer cells. Pre-clinical studies were undertaken …

OBJECTIVE: Endometrial cancer models are critical to the advancement of investigation,
and Ishikawa H and Hec50co cells have been used as research tools. The purpose of these …

Progesterone, acting through its receptor, PR (progesterone receptor), is the natural inhibitor
of uterine endometrial carcinogenesis by inducing differentiation. PR is downregulated in …

Aberrant DNA methylation is an important molecular alteration commonly detected in
various malignancies. Hypermethylation and expression silencing have been frequently …

Breast and endometrial cancers are the most common invasive malignancies in women,
with more than 217,000 new diagnoses per year in the United States. These cancers are …